Columbia professor warns that many DATs were launched as get-rich-quick schemes.Columbia professor warns that many DATs were launched as get-rich-quick schemes.

Many Crypto Treasury Companies Were a Get-Rich-Quick Trap, Warns Columbia Professor

Columbia Business School professor Omid Malekan said that any analysis of why crypto prices continue to fall needs to include Digital Asset Treasuries (DATs), because in aggregate, they turned out to be a mass extraction and exit event, which is a reason for prices to go down.

He said there are a few exceptions, but he added that he can count them on one hand. Meanwhile, “dozens upon dozens” were launched in a fashion likely to cause value destruction for crypto assets. He argued that, based on his interactions, many of the people launching DATs viewed the model as a get-rich-quick scheme.

Inside the DAT Frenzy

Malekan pointed to jittery investor presentations that glossed over important details, the excessive use of empty buzzwords, and the absence of basic disclosure, including who was being paid. In his tweet, the professor said that the intent behind many of these launches was obvious.

Malekan explained that launching any kind of public entity is expensive, and the money required for the shell / PIPE / SPAC runs into the millions, as do the fees paid to all the bankers and lawyers involved. He pointed out that the money spent on those fees had to come from somewhere.

He also said there were shady “advisory agreement” deals many DATs had, seldom disclosed in the marketing materials, and noted that the money spent on those had to come from somewhere, too. He also shed light on the inherent conflicts of interest of DATs appointing founders or VCs to their boards, then channeling shareholder money to their startups or PortCos.

Malekan said the biggest damage DATs did to the aggregate crypto market cap was by providing a mass exit event for supposedly locked tokens, and he said he is still amazed so many other investors did not cry foul over this. According to him, many alts had far greater circulating supply, and markets are a discounting mechanism, and the easiest thing to discount is “more supply than anticipated.”

VanEck Flags Weakness in DAT Model

Last month, VanEck warned that the DAT model is risky because it relies directly on volatility, and volatility is structurally declining in Bitcoin as adoption grows. According to the global investment management firm, a DAT needs ongoing price swings to fund asset purchases, and a long-term trend toward dampened volatility threatens the core economics of the model itself.

VanEck also flagged structural market issues within this segment and noted that many of the new entrants do not have deep or liquid enough options markets to price risk efficiently. This could eventually leave the “volatility well” depleted and reduce the ability of DATs to purchase assets.

The post Many Crypto Treasury Companies Were a Get-Rich-Quick Trap, Warns Columbia Professor appeared first on CryptoPotato.

Market Opportunity
Ostrich Logo
Ostrich Price(RICH)
$0.0001
$0.0001$0.0001
-16.66%
USD
Ostrich (RICH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26